University of Virginia Cancer Center

Corbus Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, November 7, 2023
Rimonabant, NSCLC, Food, Biomarker, Doctor of Philosophy, CB1, Breast cancer, University of Virginia Cancer Center, SITC, The Obesity Society, Head, CSPC, FACP, Human, Therapeutic index, Cleavage, Yale School of Medicine, Society for Immunotherapy of Cancer, Mouse, DIO, Immunotherapy, University, Hand, Investment, Patient, Monoclonal antibody, Food and Drug Administration Amendments Act of 2007, Plasma, Conference, Liraglutide, Development, ADC, Brain, Insulin resistance, Society, AACR, IND, Manuscript, Poster, MMAE, Semaglutide, Tumor microenvironment, Carcinoma, Mab, Neck, Medical imaging, Vaccine, Soft drink, Pharmaceutical industry, Corbus, MD, Obesity

“The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.

Key Points: 
  • “The third quarter was a productive period for Corbus as data was presented for each of our three programs at relevant scientific conferences” said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus.
  • Finally, we presented the first ever comprehensive data on CRB-913, our highly peripherally restricted cannabinoid type-1 receptor (CB1) inverse agonist.
  • Early clinical experience will be shared in Q1 2024, which will coincide with the initiation of a U.S./EU trial by Corbus.
  • Corbus presented two posters at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) held on November 1 - 5, 2023.

Specific Biologics Announces Additional Investment and Appointment of Experienced Biotechnology Leader Steven Kanner, PhD, to the Board of Directors

Retrieved on: 
Tuesday, October 10, 2023
ADMAR, Cystic Fibrosis Foundation, MBA, Doctor of Philosophy, Research, Pregnancy specific biological substances, G.H. Raisoni Department of Microbiology and Biotechnology, Bristol Myers Squibb, Berkeley, MD, Master of Science, Organization, Therapy, Liver, Genetics, University, Mutation, Rachel Haurwitz, Disease, University of Miami Division of Surgical Neurooncology, Arrowhead Pharmaceuticals, Leonard M. Miller School of Medicine, Cystic fibrosis, Annual Review of Cancer Biology, University of Virginia Cancer Center, Acute leukemia, DSM-IV codes, Gene editing, Astex Pharmaceuticals, Specific, Dasatinib, CNS, Patient, Vaccine, Pharmaceutical industry, Investment, Microbiology, Immunology

Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.

Key Points: 
  • Specific Biologics is an early-stage biotechnology company developing its proprietary two-site Dualase® platform gene editors to build a pipeline of treatments for serious genetic diseases.
  • TORONTO, Oct. 10, 2023 /PRNewswire/ - Specific Biologics Inc. ("Specific"), a venture-backed, early-stage genome editing company, is pleased to announce it has appointed Steven Kanner, PhD, as an Independent Director.
  • The appointment coincides with renewed investment from Lumira Ventures and adMare BioInnovations to advance the preclinical development of therapeutics based on Specific's proprietary Dualase® platform gene editors.
  • The additional investment from Lumira Ventures and adMare BioInnovations will be used to advance preclinical testing of Dualase gene editors in liver, ocular and CNS disorders.

Corbus Pharmaceuticals to Host Virtual ‘Meet the Expert’ Series (Session 2) on CRB-701 on October 10, 2023

Retrieved on: 
Tuesday, October 3, 2023
Oncology, Yale School of Medicine, University, CSO, Head, FACP, GU, NSCLC, University of Virginia Cancer Center, Doctor of Philosophy, Biology, ADC, Neck, Breast cancer, Fine chemical, Management, Vaccine, MD, Corbus

The focus for this discussion is on the Nectin-4 targeting ADC (CRB-701) and the diverse indications relevant to its development.

Key Points: 
  • The focus for this discussion is on the Nectin-4 targeting ADC (CRB-701) and the diverse indications relevant to its development.
  • The discussion will define unmet needs, Nectin-4 biology and the features of differentiation in the design of CRB-701 relative to enfortumab vedotin (PADCEV).
  • The panel comprises 3 medical oncologists covering GU, H&N and NSCLC tumors as well as a breast /translational expert.
  • The panel will be moderated by Rachael Brake, PhD, CSO of Corbus.

Vera Bradley Foundation for Breast Cancer Raises $1,513,713 for Breast Cancer Research

Retrieved on: 
Monday, September 18, 2023
Volunteering, Partnership, Roswell Park Comprehensive Cancer Center, Indiana University School of Medicine, Hope, Research, University of Virginia Cancer Center, Breast Cancer Awareness Month, National Cancer Institute, Breast cancer, School, Classic, NCI, National Breast Cancer Foundation (Australia), Disease, Dietary supplement, Medicine

FORT WAYNE, Ind., Sept. 17, 2023 (GLOBE NEWSWIRE) -- The Vera Bradley Foundation for Breast Cancer (the "Foundation") today announced a donation of $1,513,713 to support the Vera Bradley Foundation Center for Breast Cancer Research at the Indiana University School of Medicine (“IU School of Medicine”).

Key Points: 
  • FORT WAYNE, Ind., Sept. 17, 2023 (GLOBE NEWSWIRE) -- The Vera Bradley Foundation for Breast Cancer (the "Foundation") today announced a donation of $1,513,713 to support the Vera Bradley Foundation Center for Breast Cancer Research at the Indiana University School of Medicine (“IU School of Medicine”).
  • The Foundation’s donation announcement was shared at the 29th annual Vera Bradley Foundation for Breast Cancer Classic (the “Classic”), which gathered guests, players, and volunteers from across the country to raise funds for breast cancer research.
  • More than 35 members of the Vera Bradley Foundation Center for Breast Cancer Research team at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center (the “IU Cancer Center”) work collaboratively with laboratory, clinical, translational and population/prevention researchers in a multi-disciplinary approach.
  • “For the past 30 years, the Vera Bradley Foundation for Breast Cancer has been steadfastly committed to raising funds for breast cancer research,” noted Stephanie Scheele, Executive Director of the Vera Bradley Foundation for Breast Cancer.

Aster Insights announces that The University of Kansas Cancer Center will join the Oncology Research Information Network (ORIEN)

Retrieved on: 
Friday, June 2, 2023
University, KUCC, Cancer, Research, TCC, Patient, Collection, Health, NCI, University of Virginia Cancer Center, Pharmaceutical industry

TAMPA, Fla. and KANSAS CITY, Kan., June 2, 2023 /PRNewswire/ -- Aster Insights, the leading provider of technology-enabled data and analytics solutions for oncology discovery, today announced The University of Kansas Cancer Center will join its Oncology Research Information Exchange Network (ORIEN). The KU Cancer Center will be the latest NCI-designated cancer center to join ORIEN, which is comprised of 18 cancer centers across the U.S. dedicated to collaborative research to accelerate cancer discovery and development.

Key Points: 
  • TAMPA, Fla. and KANSAS CITY, Kan., June 2, 2023 /PRNewswire/ -- Aster Insights , the leading provider of technology-enabled data and analytics solutions for oncology discovery, today announced The University of Kansas Cancer Center will join its Oncology Research Information Exchange Network ( ORIEN ).
  • "We are thrilled to welcome Kansas to ORIEN," said Dr. George Weiner, Chairman of the ORIEN Steering Committee, and Cancer Center Director Emeritus at University of Iowa Holden Cancer Center.
  • "I am familiar with the remarkable strengths at The University of Kansas Cancer Center, including its cancer bioinformatics research capabilities.
  • "The KU Cancer Center is proud to join ORIEN and work alongside this outstanding network of academic cancer centers," said Dr. Roy Jensen, vice chancellor and director of The University of Kansas Cancer Center.

First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma

Retrieved on: 
Monday, April 17, 2023
Well, Class II, RECIST, DL 2, A2, MEK, Doctor of Philosophy, Plasma, MD, Patient, Carcinoma, KNTE, PRS, MBBS, Half-life, Response evaluation criteria in solid tumors, FACP, University of Virginia Cancer Center, Lung cancer, Binimetinib, Combination therapy, Neoplasm, Grade, Abstract, Skin, PR, Safety, RAF, NRAS, DNA, Index, AACR, Alanine transaminase, Papillary thyroid cancer, American Association for Cancer Research, BRAF, NSCLC, IC50, Colorectal cancer, SAN, MTD, ORR, Probability, Grade 3, Trae tha Truth, Part, Physician, Melanoma, Annual general meeting, Toxic leukoencephalopathy, SD, Pharmaceutical industry, Vaccine, Phosphorus, Generic drug, Medical imaging, Nursing, Cmax

“The exarafenib dose escalation data provide striking proof of concept for a monotherapy pan-RAF inhibitor,” said Alexander Spira, MD, PhD, FACP, co-director, Virginia Cancer Specialists Research Institute.

Key Points: 
  • “The exarafenib dose escalation data provide striking proof of concept for a monotherapy pan-RAF inhibitor,” said Alexander Spira, MD, PhD, FACP, co-director, Virginia Cancer Specialists Research Institute.
  • Treated patients included those with solid tumors driven by BRAF Class I (41.7%), Class II (13.3%) and Class III (30%) alterations or melanoma with NRAS mutations (15%).
  • Dose limiting toxicities observed at the highest dose level (400 mg bid) were Grade 3 acneiform rash (n=1) and Grade 3 macular rash (n=1).
  • Kinnate will prioritize development of the exarafenib combination in patients with NRAS mutant melanoma.

Jefferson Collaborates with MDClone to Accelerate Academic Research

Retrieved on: 
Monday, November 14, 2022
Magnet, Ecosystem, Jefferson Health, Children's Health Insurance Program, National Cancer Registrars Association, Health Partners Plans, Environment, Population, National Cancer Institute, Medicaid, Student, Organization, Partnership, Privacy, School, Population health, University of Virginia Cancer Center, Education, Research, Next, Patient, ANCC, Child, Thomas Jefferson University, Friction, CEO, Hospital, Science, Health information management, Jefferson College, Solution, Pharmaceutical industry, Medicine

PHILADELPHIA, Nov. 14, 2022 /PRNewswire/ -- MDClone, a leading data analytics and synthetic data company, and Thomas Jefferson University and Jefferson Health today announced a partnership in which Jefferson will leverage MDClone's innovative synthetic data platform to accelerate academic research.

Key Points: 
  • PHILADELPHIA, Nov. 14, 2022 /PRNewswire/ -- MDClone , a leading data analytics and synthetic data company, and Thomas Jefferson University and Jefferson Health today announced a partnership in which Jefferson will leverage MDClone's innovative synthetic data platform to accelerate academic research.
  • The MDClone ADAMS Platform is a powerful, self-service data analytics environment that enables healthcare collaboration, research, and innovation.
  • By making real-world data easier to access, the ADAMS Platform will help Jefferson researchers reduce the friction points to formulating academic research questions, identifying relevant data, analyzing the data, and producing results.
  • Jefferson's clinical arm, Jefferson Health, is an 18-hospital health system based in Philadelphia that is home to nationally ranked experts.

Dr. David Weintritt Brings Innovative Treatment to Breast Cancer Patients in Northern Virginia

Retrieved on: 
Monday, October 3, 2022
Air force, Physician, Perfusion, Health, DC, Multimedia, University of Virginia Cancer Center, View, Breast disease, Andrews Air Force Base, Walter Reed Army Medical Center, University, Lymph, Quality of life, Breast cancer, Patient, United, Private practice, FACS, Woman, Birth control, Medicine, Medical imaging, MD

FAIRFAX, Va., Oct. 3, 2022 /PRNewswire/ -- Virginia Cancer Specialists is proud to announce that David Weintritt, MD, FACS, one of the nation's most innovative breast surgeons, is joining their community-based cancer treatment team.

Key Points: 
  • FAIRFAX, Va., Oct. 3, 2022 /PRNewswire/ -- Virginia Cancer Specialists is proud to announce that David Weintritt, MD, FACS, one of the nation's most innovative breast surgeons, is joining their community-based cancer treatment team.
  • Weintritt says Virginia Cancer Specialists offers him the opportunity to practice in a holistic environment where all the needs of patients can be met through the resources Virginia Cancer Specialists has to offer.
  • "With his focus on promising new surgical advancements in breast cancer treatment, Dr. Weintritt is a welcome addition to our breast cancer team as we seek to deliver the very best in integrated care to our breast patients."
  • In 2003, Dr. Weintritt moved his practice to Alexandria, VA, bringing new programs and breast surgery techniques to Northern Virginia.

Investigators from US Oncology Research, The US Oncology Network and Ontada Present Data Highlighting Key Advances and Insights at the 2022 American Society of Clinical Oncology Annual Meeting

Retrieved on: 
Friday, June 3, 2022
Pharmaceutical, Health, Oncology, Interview, Texas Oncology, PARP, Lung, Doctor of Philosophy, Hope, Digital, Machine learning, ATHENA, Technology, The Network, McKesson Corporation, Research, FACP, Pragmatism, Public policy, Hospice, Network, Cancer, Hospital, Histology, Knowledge, MBA, Pharmacist, Partnership, Delivery, Solution, Ovarian cancer, Trial of the century, Health, MD, ICU, Patient, CNS, Bevacizumab, ML, Large-cell lung carcinoma, Rucaparib, University of Virginia Cancer Center, Abstract, Doctor of Pharmacy, MET, Physician, Education, Woman, Science, Society, ADP, ASCO, Â, Annual general meeting, Maintenance, American Society of Clinical Oncology, FDA, Clinical trial, Health literacy, Safety, Medical imaging, Medicine, Pharmaceutical industry, Medical device, NSCLC, Poly

During the scientific program of the 2022 American Society of Clinical Oncology ( ASCO ) Annual Meeting, principal investigators from US Oncology Research , The US Oncology Network (The Network) and Ontada will present detailed results from more than 80 studies.

Key Points: 
  • During the scientific program of the 2022 American Society of Clinical Oncology ( ASCO ) Annual Meeting, principal investigators from US Oncology Research , The US Oncology Network (The Network) and Ontada will present detailed results from more than 80 studies.
  • Protocol 2 of the study platform included an examination of an oncology clinical pharmacist on the research team and the impact on clinical trial enrollment.
  • You can find the full schedule of affiliated data presentations from US Oncology Research, The US Oncology Network and Ontada including author details, here .
  • US Oncology Research draws from a network of experienced investigators and dedicated clinical staff who specialize in oncology clinical trials.

Rubius Therapeutics to Host Investor Webcast to Discuss Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Patients with Advanced Solid Tumors on April 8, 2022, at 1:15 PM ET

Retrieved on: 
Thursday, April 7, 2022
Rubius, Thorax, Therapy, LinkedIn, Degenerative disease, Investor, El Rubius, University of Virginia Cancer Center, ID, The Boston Globe, News, Red Cell, Providence Business News, Cancer, RED, Twitter, Nasdaq, GLOBE, Patient, Pharmaceutical industry, Facebook

The audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website.

Key Points: 
  • The audio webcast will be available on the Events and Presentations page within the Investors and Media section of the Rubius Therapeutics website.
  • The update may also be accessed by dialing (800) 289-0045 (domestic) or (615) 622-8086 (international) five minutes prior to the start of the call.
  • Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics.
  • For more information, visit www.rubiustx.com , follow us on Twitter or LinkedIn or like us on Facebook .